Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19

Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19

Background and Aim: Tocilizumab, a humanized anti-IL-6 receptor antibody, has been used to treat severely to critically ill patients with COVID-19. A living systematic review with meta-analysis of recent RCTs indicates that the combination therapy of corticosteroids and tocilizumab produce better ou...

Full description

Bibliographic Details
Main Authors: Shoji Hashimoto, Kazuyuki Yoshizaki, Kazuko Uno, Heita Kitajima, Tsuyoshi Arai, Yoshitaka Tamura, Hiroshi Morishita, Hiroto Matsuoka, Yuki Han, Seijiro Minamoto, Tomonori Hirashima, Tomoki Yamada, Yozo Kashiwa, Makoto Kameda, Seiji Yamaguchi, Yasunari Tsuchihashi, Mitsuhiro Iwahashi, Emi Nakayama, Tatsuo Shioda, Takayuki Nagai, Toshio Tanaka
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Medicine
Subjects:
COVID-19
cytokine storm
IL-6
tocilizumab
dexamethasone
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.734838/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.734838/full

Similar Items